SCHEMBL866088

SCHEMBL866088

NCCCCC(N)(C(=O)O)C(F)F

nearest known ligand 0.89

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ODC1 P11926 2/20 0.89
LMNA P02545 3/20 0.85
BLM P54132 3/20 0.85
KDM4E B2RXH2 1/20 0.85
MAPT P10636 1/20 0.85
RAB9A P51151 1/20 0.85
PMP22 Q01453 1/20 0.85
SMN1; SMN2 Q16637 1/20 0.85
ARG1 P05089 3/20 0.66
ARG2 P78540 2/20 0.43
CYP2D6 P10635 1/20 0.37
NFKB1 P19838 1/20 0.37
GSR P00390 1/20 0.36
NPSR1 Q6W5P4 2/20 0.35
THRB P10828 2/20 0.35
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
PLG P00747 1/20 0.35
ALOX15 P16050 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL866087 1.00 ODC1 (0.89) ODC1LMNABLMKDM4EMAPT
Hydrochloric Acid SCHEMBL10999722 0.98 BLM (0.89) ODC1LMNABLMKDM4EMAPT
Hydrochloric Acid SCHEMBL11001948 0.98 BLM (0.89) ODC1LMNABLMKDM4EMAPT
Eflornithine SCHEMBL26327 0.94 ODC1 (1.00) ODC1LMNABLMKDM4EMAPT
Eflornithine SCHEMBL8581344 0.94 ODC1 (1.00) ODC1LMNABLMKDM4EMAPT
D-Eflornithine SCHEMBL60699 0.94 ODC1 (1.00) ODC1LMNABLMKDM4EMAPT
Eflornithine, (S)- SCHEMBL60698 0.94 ODC1 (1.00) ODC1LMNABLMKDM4EMAPT
D-Eflornithine SCHEMBL3244719 0.92 ODC1 (0.96) ODC1LMNABLMKDM4EMAPT
Eflornithine, (S)- SCHEMBL1322403 0.92 BLM (1.00) ODC1LMNABLMKDM4EMAPT
Eflornithine SCHEMBL3244711 0.92 ODC1 (0.96) ODC1LMNABLMKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250197916-A1 METHODS AND COMPOSITIONS FOR SUPPRESSION OF BIOGENIC AMINES PRODUCED BY THE GUT MICROBIOME CEDARS-SINAI MEDICAL CENTER (US) 2025-06-19 US claimed
US-20140255991-A1 OVEREXPRESSION OF AMINOACYL-tRNA SYNTHETASES FOR EFFICIENT PRODUCTION OF ENGINEERED PROTEINS CONTAINING AMINO ACID ANALOGUES CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2014-09-11 US claimed
US-20120077228-A1 OVEREXPRESSION OF AMINOACYL-tRNA SYNTHETASES FOR EFFICIENT PRODUCTION OF ENGINEERED PROTEINS CONTAINING AMINO ACID ANALOGUES CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2012-03-29 US claimed
US-20080160609-A1 Dihydrofolate reductase; site directed mutagenesis; point mutations; auxotroph host cells CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2008-07-03 US claimed
US-6187296-B1 SUCH AS ALPHA-DIFLUOROMETHYL LYSINE (DEML) OR ALPHA-MONOFLUOROMETHYL LYSINE (MFML) THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA 2001-02-13 US claimed
US-6103220-A Lysine decarboxylase inhibitors for the prevention and treatment of periodontal disease THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA 2000-08-15 US claimed
US-4560795-A α-Halomethyl derivatives of α-amino acids Merrell Dow France et Cie. (FR) 1985-12-24 US claimed
US-4496588-A HALOMETHYL DERIVATIVES OF A-AMINO ACID MERRELL TORAUDE ET COMPAGNIE (FR) 1985-01-29 US claimed
US-20250197916-A1 METHODS AND COMPOSITIONS FOR SUPPRESSION OF BIOGENIC AMINES PRODUCED BY THE GUT MICROBIOME CEDARS-SINAI MEDICAL CENTER (US) 2025-06-19 US disclosed
US-20250156160-A1 SYSTEM AND METHOD FOR AUTOMATED MAPPING OF DATA TYPES FOR USE WITH DATAFLOW ENVIRONMENTS ORACLE INTERNATIONAL CORPORATION 2025-05-15 US disclosed
US-20250156160-A1 SYSTEM AND METHOD FOR AUTOMATED MAPPING OF DATA TYPES FOR USE WITH DATAFLOW ENVIRONMENTS ORACLE INTERNATIONAL CORPORATION 2025-05-15 US disclosed
US-12282757-B2 System and method for automated mapping of data types for use with dataflow environments ORACLE INTERNATIONAL CORPORATION (US) 2025-04-22 US disclosed
US-12282757-B2 System and method for automated mapping of data types for use with dataflow environments ORACLE INTERNATIONAL CORPORATION (US) 2025-04-22 US disclosed
US-20250111889-A1 DE NOVO DESIGNED MACROCYCLIC OLIGOAMIDES UNIVERSITY OF WASHINGTON 2025-04-03 US disclosed
US-4879223-A Method for producing protein containing nonprotein amino acids WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) 1989-11-07 US disclosed
EP-0288087-A2 Method for producing protein containing nonprotein amino acids WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) 1988-10-26 EP disclosed
US-4560795-A α-Halomethyl derivatives of α-amino acids Merrell Dow France et Cie. (FR) 1985-12-24 US disclosed
US-4496588-A HALOMETHYL DERIVATIVES OF A-AMINO ACID MERRELL TORAUDE ET COMPAGNIE (FR) 1985-01-29 US disclosed
US-4438270-A DECARBOXYLASE INHIBITORS MERRELL TORAUDE ET COMPAGNIE (FR) 1984-03-20 US disclosed
US-4405530-A Process for preparing fluorinated amino-nitriles MERRELL TORAUDE ET COMPAGNIE (FR) 1983-09-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250111889-A1 DE NOVO DESIGNED MACROCYCLIC OLIGOAMIDES DHFR, CCNH, ODC1 ODC1 3/4885LMNA 1387/4885BLM 96/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.